[Click eStock] "Duchem Bio, Benefiting from Growth in Radiopharmaceutical Diagnostics"

On the 20th, KB Securities analyzed that Dukem Bio is developing future growth engines based on radiopharmaceutical diagnostic agents.

Clinical researcher Lim Guk from KB Securities explained, "The increase in PET-CT demand due to the rise in Alzheimer's dementia patients, a representative disease of an aging society, will naturally lead to high growth of radiopharmaceutical diagnostic agents such as 'Bijamil' and 'Neuracheck'."

He continued, "For prescribing the Alzheimer's treatment drug 'Leqembi', it is important to accurately confirm the degree of beta-amyloid deposition," adding, "This is done using PET-CT methods with radiopharmaceutical diagnostic agents."

He said, "Since at least 1 to 3 diagnostic tests are required for Leqembi prescription and follow-up management, future growth of Dukem Bio is expected," and analyzed, "The exploration of diagnostic radiopharmaceutical candidate substances using artificial intelligence (AI), and the introduction of treatment technologies for solid cancers such as prostate cancer, as well as the establishment of diagnostic and therapeutic radiopharmaceutical pipelines, are also attractive factors."

Researcher Lim introduced, "Dukem Bio is preparing to leap forward as an Asian supply hub by expanding production capacity of diagnostic radiopharmaceuticals and establishing CDMO production facilities for therapeutic radiopharmaceuticals." He forecasted, "The annual production capacity in the dementia diagnosis sector, currently 90,000 doses, is planned to expand to 210,000 doses by 2028," and "the therapeutic radiopharmaceutical CDMO facilities will have one manufacturing plant established in 2027 and another in 2029."

This content was produced with the assistance of AI translation services.